Condition (MeSH)
Hereditary Angioedema Types I and II
ClinicalTrials.gov lists 17 trials for Hereditary Angioedema Types I and II or a narrower condition beneath it. CSL Behring has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 17 trials are tagged with Hereditary Angioedema Types I and II itself; the rest are tagged with a narrower condition beneath it.
When did Hereditary Angioedema Types I and II trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2014 | 2 |
| 2013 | 2 |
| 2012 | 1 |
| 2011 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hereditary Angioedema Types I and II trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Observational | 3 |
How many Hereditary Angioedema Types I and II trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Enrolling by invitation | 1 |
| Completed | 11 |
| Terminated | 3 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hereditary Angioedema Types I and II trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CSL Behring | 5 |
| Pharvaris Netherlands B.V. | 4 |
| Prothya Biosolutions | 3 |
| CENTOGENE GmbH Rostock | 2 |
| KalVista Pharmaceuticals, Ltd. | 1 |
Which drugs are being tested for Hereditary Angioedema Types I and II? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Deucrictibant | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| C1 inhibitor concentrate | 3 |
| C1-esterase inhibitor - subcutaneous low dose | 1 |
| Ecallantide subcutaneous dosing | 1 |
| KVD824 | 1 |
| Deucrictibant low dose | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hereditary Angioedema Types I and II trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hepatic steatosis | 2 | 1 |
| Hereditary angioedema | 2 | 2 |
| Syncope | 2 | 2 |
| Abortion spontaneous | 1 | 1 |
| Arthritis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hereditary Angioedema Types I and II? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks. | The New England journal of medicine | 2024 | Yes |
| Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. | The journal of allergy and clinical immunology. In practice | 2019 | Yes |
| Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. | JAMA | 2018 | Yes |
| Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | 2017 | Yes |
| Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. | The New England journal of medicine | 2017 | Yes |
Showing 5 of 15 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.